RenuMemo
Therapeutics

Building next-generation small-molecule combination therapy for Alzheimer’s disease

A development-focused program integrating multiple CNS-active compounds into a rationally optimized combination (RM02).

Research & Pipeline Contact

Why Alzheimer’s Disease Remains Unsolved

Despite decades of research and substantial global investment, Alzheimer’s disease continues to evade effective disease-modifying therapies.

The disease is driven by complex and interconnected biology, involving multiple pathological processes that evolve over time.

As a result, single-target therapeutic strategies have repeatedly shown limited and inconsistent clinical benefit.

Rethinking How Alzheimer’s Drugs Are Developed

For decades, the industry has focused largely on highly selective, single-target approaches.

While effective in other therapeutic areas, this strategy has struggled to address the biological complexity of Alzheimer’s disease.

This complexity suggests that coordinated modulation of multiple biological drivers may be required.

RM02: A Rational Small-Molecule Combination Program

Designed to integrate multiple CNS-active small molecules into a defined and optimized combination, RM02 translates disease complexity into a development-ready drug asset.

Learn More About RM02